An observational study in Retinopathy of Prematurity, Neurodevelopmental Disorders and Macular Edema, sponsored by Duke University. Completed at 4 sites in United States. Open to participants aged 30 Weeks and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-02-10.
Sponsored by Duke University · Observational
Retinopathy of prematurity (ROP) is a disorder of development of the neural retina and its vasculature that may impact vision in vulnerable preterm neonates for a lifetime. This study utilizes new technology to determine visual and neurological development of very preterm infants in the intensive care nursery, during a period of rapid growth of the retina, optic nerve and brain. The long-term goal of this study is to help improve preterm infant health care via objective bedside imaging and analysis that characterizes early critical indicators of poor vision, neurological development and ROP, which will rapidly translate to better early intervention and improved future vision care.
Retinopathy of prematurity (ROP) is a disorder of development of the neural retina and its vasculature that may impact vision in vulnerable preterm neonates for a lifetime. Clinical care of infants with ROP decreases the likelihood of blindness, but abnormal vision is common, especially in those with disease severe enough to require treatment. Because it has not been possible to distinguish whether disease and/or maldevelopment that affects specific retinal cells and/or the central nervous system (CNS) cause the vision loss, especially when it is less severe, there has been no strategy to prevent subnormal acuity in the majority of infants treated for ROP.
The interval that a preterm infant at risk for ROP spends in an intensive care nursery (ICN) is a time of rapid retinal development. Clinicians and researchers do not know how local, CNS and systemic development and disease processes are reflected in the retinal microanatomy. Abnormalities in the retina during infancy are likely early predictors of later vision problems and developmental delay. From study of preterm retinal substructures, brain anatomy, connectivity and functional networks and neuroinflammatory biomarkers this study will elucidate the pathway by which local retinal anatomic changes impact and may predict later subnormal vision and CNS function. The results of this research will enable the investigator to: distinguish ocular from non-ocular contributions to vision loss; guide future treatment directed to modify retinal anomalies such as edema; and determine which microanatomic retinal biomarkers are best to monitor effects of ROP, and effects of systemic therapies on the eye and brain. In contrast to indirect ophthalmoscopy or photography, novel non-contact ocular imaging at the bedside would enable direct telemedicine screening for ROP and for neural development in multiple nurseries.
The long-term goal is to help improve preterm infant health care via objective bedside imaging and analysis that characterizes early critical indicators of poor vision, neurological development and ROP. This will rapidly translate to early intervention and improved future vision care. Specific goals of this research are threefold: to implement technological innovations to improve optical coherence tomography (OCT) imaging in non-sedated infants in the ICN; to distinguish elements of retinal microanatomy which predict maldevelopment of visual pathway and poor neurodevelopment that may impact vision in preterm infants; and to delineate which elements and regions (posterior and peripheral) of preterm infant OCT-derived retinal microanatomy best inform us about severity of disease and visual outcomes in infants with ROP.
In addition to providing a breakthrough method for bedside analysis of the very preterm (VPT) infant posterior and peripheral retina, this study will provide the pediatric ophthalmologic and telemedicine community with methods to distinguish microanatomic markers that predict infants at risk for abnormal vision, visual pathway injury, poor functional development and progression of ROP (and combinations thereof). These biomarkers will be useful for determining ophthalmic and CNS therapeutic interventions and monitoring their impact on the visual pathway and will thus likely cross over with relevance to other infant eye and brain disease.
841 studies on the registry are indexed under Macular Edema; 56 are open to participants now.
This study's enrollment of 191 is above the median of 97 across 163 observational studies indexed under Macular Edema.
Browse Macular Edema studies →Duke University is the lead sponsor of 2,025 studies on the registry; 275 are open to participants now.
Of its 194 completed or terminated interventional studies of FDA-regulated products, 159 (82%) have results posted.
Counted across the registry records on this site, refreshed daily.
This study will have approximately 160 participants recruited and consented into the study at Duke University Health System. Of the 160 participants, 135 will be pediatric participants (of which 110 will be infants in the ICN) and 25 will be healthy adult volunteers. Infants in the ICN must meet the American Association of Pediatrics eligibility of ROP screening (Infants with a birth weight of ≤1500 g or gestational age of 30 weeks), and is age ≤ 34 6/7 weeks postmenstrual age at first visit.
Exclusion Criteria:
Specific Aim 1B (implement technical innovations to improve OCT imaging in non-sedated infants in the ICN: (1B) extend imaging to the vascular-avascular junction via a wide-field lens). Aim 1B only: 50 participants (25 healthy adult volunteers and 25 pediatric participants under going examination under anesthesia * Healthy adult volunteers will have SSOCT imaging of both eyes with the novel ultralight handpiece up to 10 times. * Pediatric participants undergoing examination under anesthesia will have SSOCT imaging of both eyes with the novel ultralight handpiece once during their EUA in the Duke Eye Center Operating Rooms (OR). These participants will be enrolled into the study at DUHS including the Duke Eye Center clinics and OR for testing the custom widefield lens.
Device: Swept Source OCT
Specific Aim 2 (distinguish elements of retinal microanatomy that predict maldevelopment of visual pathway and poor neurodevelopment that may impact vision in preterm infants) includes 68 very preterm infants undergoing the following during evaluation for ROP. 1. Swept Source OCT imaging of both eyes with the novel ultralight handpiece before or after ROP examination, timed with each examination. The axial length of the eye may be measured after the ROP exam. 2. Non-sedated research brain Magnetic Resonance Imaging will be obtained in 68 participants prior to discharge from the nursery whenever possible (as close to term age as possible). In the case of an early infant discharge to another hospital, every effort will be made to obtain brain MRI prior to transfer or an outpatient non-sedated brain MRI at near term age. 3. Scavenged blood collection: Residual samples of serum/plasma in the laboratory will be collected for neuroinflammatory marker testing.
Device: Swept Source OCT · Other: Magnetic Resonance Imaging · Other: Scavenged blood collection
Specific Aim 3 (delineate which elements and regions (posterior) or (peripheral) of preterm infant OCT-derived retinal microanatomy best inform us about severity of disease and visual outcomes in infants with ROP will include the same 68 participants plus an additional 42 very preterm infants undergoing evaluation for ROP and visual function but who will not be in the neurodevelopmental study and thus will not have brain MRI, 2-year Bayley Scales testing or neuroinflammatory marker testing on scavenged blood. The Specific Aim 3 subjects will undergo the following: 1. Swept Source OCT imaging of both eyes with the novel ultralight handpiece as described in Aim 2. The axial length of the eye may be measured after the ROP exam. 2. After imaging with the original lens (ultralight handpiece) both eyes will be imaged with the widefield OCT lens. before or after the ROP exam. 3. Ocular and systemic health data will be extracted from the study participant's medical record.
Device: Swept Source OCT
The swept source optical coherence tomography device was developed at Duke University as the result of collaboration between the Departments of Ophthalmology and Biomedical Engineering. The SSOCT system has a 100kHz repetition rate, 1050nm-centered swept-source light source (Axsun Technologies). This swept-source system allows near real-time OCT imaging during movement while imaging and it provides better OCT imaging of the choroid. The SSOCT system is a non-contact device and therefore does not touch the eye.
Also known as: SSOCT, Swept Source Optical Coherence Tomography
Non-sedated research brain MRI: Magnetic resonance imaging (MRI) is a minimal risk procedure that uses a magnet and radio waves to make diagnostic medical images of the body. There have been no ill effects reported from exposure to the magnetism or radio waves used in this test. However, it is possible that harmful effects could be recognized in the future. A known risk is that the magnet could attract certain kinds of metal. Therefore, we will carefully ask about metal within the body. If there is any question about potentially hazardous metal within the body, MRI imaging will not be performed. We will also keep the examining room locked so that no one carrying metal objects can enter while the child is in the scanner.
Also known as: MRI
Serum/plasma (residual in the laboratory) collected as part of clinically indicated care will be shipped to the University of Florida for neuroinflammatory biomarker testing to identify central nervous system cellular injury.
Initiate ICN research imaging with the novel ultralight hand piece and high speed SSOCT (Aim 1A)
Start-up of research imaging in the intensive care nursery using the new ultralight hand piece and swept source OCT
Time frame: 4 years
Number of infants with reproducible imaging of the peripheral vascular-avascular junction (Aim 1B)
Analysis of reproducibility of imaging of the peripheral vascular-avascular junction in infants
Time frame: 4 years
Number of microns of retinal thickness and distance from foveal to ellipsoid zone band as seen on retinal vascular imaging using infant specific automated image processing
Develop infant-specific automated image processing/analyses for retinal vascular imaging
Time frame: 3 months
Number of microns of retinal thickness and distance from foveal to ellipsoid zone band as seen from multi-layer segmentation using infant specific automated image processing (1C)
Develop infant-specific automated image processing/analyses or multi-layer segmentation
Time frame: 3 months
Retinal microanatomy grading from Swept Source Optical Coherence Tomography (SSOCT)
Grading and measurement of retinal microanatomy from SSOCT images
Time frame: 4 years
Brain MRI grading
Grading and analysis of brain MRI scans collected at approximately term-equivalent age
Time frame: 3 years
Visual acuity scores
Analyses of data from Teller Visual acuity testing at 9 months
Time frame: 3 years
Neurodevelopmental scores
Analysis of Bayley Scales-III Neurodevelopmental testing at age 2 years
Time frame: 3 years
Peripheral retinal microanatomy grading
Analyses of peripheral retinal microanatomy at the vascular-avascular junction as recorded via SSOCT
Time frame: 4 years
ROP severity grade of retinal microanatomy by OCT
Severity of ROP as determined by analysis of posterior and peripheral retinal microanatomy
Time frame: 4 years
Maximum ROP stage as determined during clinical evaluation
Analysis of maximum ROP stage per eye as determined during clinical evaluation
Time frame: 4 years
Neuroinflammatory marker scores
Analysis of left over blood samples to determine presence and severity of neuroinflammation
Time frame: 2 years
Presence of non-ROP ocular conditions
Analysis of clinical data for strabismus,, amblyopia, refractive error, nystagmus
Time frame: 4 years
ROP specifics from clinical examination
ROP specifics including zone, plus or preplus disease, stage per clock hour, vitreous hemorrhage from clinical examination
Time frame: 4 years
ROP specifics from OCT imaging
ROP specifics including zone, plus or preplus disease, stage per clock hour, vitreous hemorrhage from OCT imaging
Time frame: 4 years
Clinician's decision to treat
Analysis of the clinician's decision to treat
Time frame: 4 years
This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Duke University